Overview: Division of Surgical Oncology

Emory surgical oncologists provide multi-modality evaluation and surgical treatment as part of the Winship Cancer Institute of Emory University, Emory's cross-disciplinary cancer treatment, prevention, and research center and Georgia's first and only NCI Designated Cancer Center. In 2015, U.S. News & World Report ranked Winship as one of the nation's top 25 cancer programs for the second year in a row. The annual list ranked cancer care at Emory University Hospital through Winship the 22nd best in the country, a two point jump from 2014.

Dr. Charles Staley has been chief of the division of surgical oncology since 1995. In 2014, Dr. Staley was named Co-PI of the Winship Cancer Institute location of the National Cancer Institute's National Clinical Trials Network (NCTN) with Emory medical oncology chief Dr. Suresh Ramalingam and Emory radiation oncologist Dr. Jonathan Beitler. The NCTN is NCI's primary infrastructure for conducting phase II and III cancer clinical trials, and is expected to enroll over 17,000 patients per year with a variety of cancer types and from diverse backgrounds.

Winship emphasizes applying the latest research as quickly and responsibly as possible to patient care, giving Emory surgical oncologists the opportunity to offer ground-breaking treatment to their patients due to their involvement in progressive bench and clinical research.

The surgical oncology training program has developed and standardized significantly over the past several years by broadening the scope and measurability of the general surgery resident's learning experience during rotations. The division also offers a breast cancer fellowship officially approved by the Society of Surgical Oncology.